Mario Ezquerra Trabalon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8734925/publications.pdf

Version: 2024-02-01

109 papers	5,593 citations	117571 34 h-index	95218 68 g-index
111 all docs	111 docs citations	111 times ranked	7310 citing authors

#	Article	IF	Citations
1	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 267-282.	1.5	21
2	Differential Phosphoâ€Signatures in Blood Cells Identify <scp>LRRK2 G2019S</scp> Carriers in Parkinson's Disease. Movement Disorders, 2022, 37, 1004-1015.	2.2	9
3	Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study. Movement Disorders, 2022, 37, 857-864.	2.2	15
4	Altered expression of the immunoregulatory ligand-receptor pair CD200-CD200R1 in the brain of Parkinsonâ€™s disease patients. Npj Parkinson's Disease, 2022, 8, 27.	2.5	8
5	Smoking is associated with age at disease onset in Parkinson's disease. Parkinsonism and Related Disorders, 2022, 97, 79-83.	1.1	2
6	The Interaction between <scp>HLAâ€ÐRB1</scp> and Smoking in Parkinson's Disease Revisited. Movement Disorders, 2022, 37, 1929-1937.	2.2	4
7	Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinsonâ€™s disease. Neurobiology of Aging, 2021, 97, 148.e17-148.e24.	1.5	16
8	Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. JAMA Neurology, 2021, 78, 464.	4.5	95
9	Regulatory rare variants of the dopaminergic gene ANKK1 as potential risk factors for Parkinsonâ€™s disease. Scientific Reports, 2021, 11, 9879.	1.6	4
10	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	2.8	29
11	Transcriptome analysis in LRRK2 and idiopathic Parkinsonâ€™s disease at different glucose levels. Npj Parkinson's Disease, 2021, 7, 109.	2.5	1
12	Finding genetically-supported drug targets for Parkinsonâ€™s disease using Mendelian randomization of the druggable genome. Nature Communications, 2021, 12, 7342.	5.8	44
13	CCAAT/enhancer binding protein Î´ is a transcriptional repressor of Î±-synuclein. Cell Death and Differentiation, 2020, 27, 509-524.	5.0	14
14	<scp>MicroRNA</scp> Deregulation in Blood Serum Identifies Multiple System Atrophy Altered Pathways. Movement Disorders, 2020, 35, 1873-1879.	2.2	15
15	Peripheral insulin and amylin levels in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 79, 91-96.	1.1	20
16	Disrupted Mitochondrial and Metabolic Plasticity Underlie Comorbidity between Age-Related and Degenerative Disorders as Parkinson Disease and Type 2 Diabetes Mellitus. Antioxidants, 2020, 9, 1063.	2.2	8
17	Transcriptomic differences in MSA clinical variants. Scientific Reports, 2020, 10, 10310.	1.6	7
18	Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score. Movement Disorders, 2020, 35, 774-780.	2.2	57

#	Article	IF	Citations
19	MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinsonâ€™s Disease Patients. Molecular Neurobiology, 2019, 56, 2092-2100.	1.9	17
20	Whole-genome DNA hyper-methylation in iPSC-derived dopaminergic neurons from Parkinsonâ€™s disease patients. Clinical Epigenetics, 2019, 11, 108.	1.8	16
21	Accumulation of mitochondrial 7S DNA in idiopathic and LRRK2 associated Parkinson's disease. EBioMedicine, 2019, 48, 554-567.	2.7	28
22	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	4.9	1,414
23	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	2.2	47
24	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. Movement Disorders, 2019, 34, 460-468.	2.2	66
25	SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease. Movement Disorders, 2019, 34, 1333-1344.	2.2	21
26	Cerebrospinal fluid cytokines in multiple system atrophy: A cross-sectional Catalan MSA registry study. Parkinsonism and Related Disorders, 2019, 65, 3-12.	1.1	26
27	Mitochondria function associated genes contribute to Parkinsonâ€™s Disease risk and later age at onset. Npj Parkinson's Disease, 2019, 5, 8.	2.5	95
28	Moving beyond neurons: the role of cell type-specific gene regulation in Parkinsonâ€™s disease heritability. Npj Parkinson's Disease, 2019, 5, 6.	2.5	83
29	HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	3.1	55
30	Parkinsonâ€™s disease as a systemic pathology. Aging, 2019, 11, 1081-1082.	1.4	3
31	Mitochondrial and autophagic alterations in skin fibroblasts from Parkinson disease patients with Parkin mutations. Aging, 2019, 11, 3750-3767.	1.4	25
32	Î±â€synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucineâ€rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain. Movement Disorders, 2018, 33, 637-641.	2.2	25
33	Target-enriched sequencing of chromosome 17q21.31 in sporadic tauopathies reveals no candidate variants. Neurobiology of Aging, 2018, 66, 177.e7-177.e10.	1.5	1
34	Transcriptional alterations in skin fibroblasts from Parkinson's disease patients with parkin mutations. Neurobiology of Aging, 2018, 65, 206-216.	1.5	13
35	The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against Î±-Synuclein-Induced Toxicity. Molecular Neurobiology, 2018, 55, 7533-7552.	1.9	40
36	Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy. Parkinsonism and Related Disorders, 2018, 46, 16-23.	1.1	32

#	Article	IF	Citations
37	LRP10 in Î±-synucleinopathies. Lancet Neurology, The, 2018, 17, 1032.	4.9	15
38	Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2 G2019S -Parkinsonâ€™s disease. Journal of Translational Medicine, 2018, 16, 160.	1.8	22
39	MicroRNA alterations in iPSC-derived dopaminergic neurons from Parkinson disease patients. Neurobiology of Aging, 2018, 69, 283-291.	1.5	55
40	MAPT association with REM sleep behavior disorder. Neurology: Genetics, 2017, 3, e131.	0.9	10
41	CSF microRNA Profiling in Alzheimerâ€™s Disease: a Screening and Validation Study. Molecular Neurobiology, 2017, 54, 6647-6654.	1.9	45
42	Lack of evidence for a role of genetic variation in TMEM230 in the risk for Parkinson's disease in the Caucasian population. Neurobiology of Aging, 2017, 50, 167.e11-167.e13.	1.5	24
43	Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimerâ€™s Disease: Potential and Limitations. Molecular Neurobiology, 2017, 54, 5550-5562.	1.9	119
44	Discovering the 3â€² UTR-mediated regulation of alpha-synuclein. Nucleic Acids Research, 2017, 45, 12888-12903.	6.5	32
45	Epigenetic Research of Neurodegenerative Disorders Using Patient iPSC-Based Models. Stem Cells International, 2016, 2016, 1-16.	1.2	13
46	Reply. Annals of Neurology, 2016, 79, 161-163.	2.8	3
47	Reply. Annals of Neurology, 2016, 79, 868-868.	2.8	0
48	Absence of LRRK2 mutations in a cohort of patients with idiopathic REM sleep behavior disorder. Neurology, 2016, 86, 1072-1073.	1.5	30
49	Aberrant epigenome in <scp>iPSC</scp> â€derived dopaminergic neurons from Parkinson's disease patients. EMBO Molecular Medicine, 2015, 7, 1529-1546.	3.3	117
50	Reply. Annals of Neurology, 2015, 78, 153-154.	2.8	1
51	The <scp>MC1R</scp> melanoma risk variant p.<scp>R160W</scp> is associated with <scp>P</scp>arkinson disease. Annals of Neurology, 2015, 77, 889-894.	2.8	52
52	TREM2 R47H variant and risk of essential tremor: A cross-sectional international multicenter study. Parkinsonism and Related Disorders, 2015, 21, 306-309.	1.1	28
53	Micro<scp>RNA</scp> association with synucleinopathy conversion in rapid eye movement behavior disorder. Annals of Neurology, 2015, 77, 895-901.	2.8	50
54	An exome study of Parkinsonâ€™s disease in Sardinia, a Mediterranean genetic isolate. Neurogenetics, 2015, 16, 55-64.	0.7	20

#	Article	IF	Citations
55	Nonmotor Symptoms in LRRK2 G2019S Associated Parkinsonâ€™s Disease. PLoS ONE, 2014, 9, e108982.	1.1	79
56	Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinsonâ€™s disease. Cell Death and Disease, 2014, 5, e1364-e1364.	2.7	40
57	Identification of blood serum microâ€RNAs associated with idiopathic and LRRK2 Parkinson's disease. Journal of Neuroscience Research, 2014, 92, 1071-1077.	1.3	122
58	Fused in Sarcoma (FUS) gene mutations are not a frequent cause of essential tremor in Europeans. Neurobiology of Aging, 2013, 34, 2441.e9-2441.e11.	1.5	22
59	Phenotypic Variability Within the Inclusion Body Spectrum of Basophilic Inclusion Body Disease and Neuronal Intermediate Filament Inclusion Disease in Frontotemporal Lobar Degenerations With FUS-Positive Inclusions. Journal of Neuropathology and Experimental Neurology, 2012, 71, 795-805.	0.9	18
60	Age at Onset in LRRK2-Associated PD is Modified by SNCA Variants. Journal of Molecular Neuroscience, 2012, 48, 245-247.	1.1	34
61	Diseaseâ€specific phenotypes in dopamine neurons from human iPSâ€based models of genetic and sporadic Parkinson's disease. EMBO Molecular Medicine, 2012, 4, 380-395.	3.3	501
62	Brain transcriptomic profiling in idiopathic and LRRK2-associated Parkinson's disease. Brain Research, 2012, 1466, 152-157.	1.1	30
63	Microarray expression analysis in idiopathic and LRRK2-associated Parkinson's disease. Neurobiology of Disease, 2012, 45, 462-468.	2.1	33
64	LRRK2 haplotypeâ€sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation. Movement Disorders, 2012, 27, 146-150.	2.2	19
65	High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal Î²-amyloid in Parkinson disease. Neuroscience Letters, 2011, 487, 169-173.	1.0	18
66	Different MAPT haplotypes are associated with Parkinson's disease and progressive supranuclear palsy. Neurobiology of Aging, 2011, 32, 547.e11-547.e16.	1.5	32
67	Identifying the genetic components underlying the pathophysiology of movement disorders. The Application of Clinical Genetics, 2011, 4, 81.	1.4	1
68	Lack of interaction of SNCA and MAPT genotypes in Parkinson's disease. European Journal of Neurology, 2011, 18, e32-e32.	1.7	12
69	123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations. Journal of Neurology, 2011, 258, 1126-1132.	1.8	31
70	LINGO1 gene analysis in Parkinson's disease phenotypes. Movement Disorders, 2011, 26, 722-727.	2.2	17
71	Rapidly progressive diffuse Lewy body disease. Movement Disorders, 2011, 26, 1316-1323.	2.2	56
72	Reply: Rapidly progressing diffuse Lewy body disease. Movement Disorders, 2011, 26, 2585-2585.	2.2	0

#	Article	IF	Citations
73	Parkinsonism, dysautonomia, REM behaviour disorder and visual hallucinations mimicking synucleinopathy in a patient with progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 578-579.	0.9	17
74	5â€²-upstream variants of CRHR1 and MAPT genes associated with age at onset in progressive supranuclear palsy and cortical basal degeneration. Neurobiology of Disease, 2009, 33, 164-170.	2.1	24
75	Cerebrospinal tau, phosphoâ€tau, and betaâ€amyloid and neuropsychological functions in Parkinson's disease. Movement Disorders, 2009, 24, 2203-2210.	2.2	163
76	G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. BMJ Case Reports, 2009, 2009, bcr0820080632-bcr0820080632.	0.2	11
77	Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration. Journal of Neurology, 2008, 255, 488-494.	1.8	40
78	Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. Journal of the Neurological Sciences, 2008, 270, 94-98.	0.3	35
79	Lack of association of APOE and tau polymorphisms with dementia in Parkinsonâ€™s disease. Neuroscience Letters, 2008, 448, 20-23.	1.0	54
80	G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 626-628.	0.9	90
81	A novel MAPT mutation (P301T) associated with familial frontotemporal dementia. European Journal of Neurology, 2007, 14, e9-10.	1.7	16
82	A novel mutation in the PSEN1 gene (L286P) associated with familial earlyâ€onset dementia of Alzheimer type and lobar haematomas. European Journal of Neurology, 2007, 14, 1409-1412.	1.7	23
83	Increased cerebral activity in Parkinson?s disease patients carrying the DRD2 TaqIA A1 allele during a demanding motor task: a compensatory mechanism?. Genes, Brain and Behavior, 2007, 6, 588-592.	1.1	14
84	Tau and saitohin gene expression pattern in progressive supranuclear palsy. Brain Research, 2007, 1145, 168-176.	1.1	10
85	Late-onset frontotemporal dementia associated with a novel PGRN mutation. Journal of Neural Transmission, 2007, 114, 1051-1054.	1.4	13
86	Brain tau expression and correlation with the H1/H1 tau genotype in frontotemporal lobar degeneration patients. Journal of Neural Transmission, 2007, 114, 1585-1588.	1.4	6
87	No evidence of CRHR1 gene involvement in progressive supranuclear palsy. Neuroscience Letters, 2006, 409, 61-64.	1.0	2
88	LRRK2 Mutations in Spanish Patients With Parkinson Disease. Archives of Neurology, 2006, 63, 377.	4.9	127
89	A Novel Intronic Mutation in the DDP1 Gene in a Family With X-linked Dystonia-Deafness Syndrome. Archives of Neurology, 2005, 62, 306.	4.9	30
90	Association study of the G258S transferrin gene polymorphism and Parkinson's disease in the Spanish population. Journal of Neurology, 2005, 252, 1269-1270.	1.8	10

#	Article	IF	Citations
91	Novel haplotypes in 17q21 are associated with progressive supranuclear palsy. Annals of Neurology, 2004, 56, 249-258.	2.8	71
92	Ubiquitin-negative mini-pick-like bodies in the dentate gyrus in p301l tauopathy. Journal of Alzheimer's Disease, 2004, 5, 445-454.	1.2	16
93	Primary progressive aphasia as the initial manifestation of corticobasal degeneration and unusual tauopathies. Acta Neuropathologica, 2003, 106, 419-435.	3.9	67
94	Mutational study of the nuclear factor kappa B inducing kinase gene in patients with progressive supranuclear palsy. Neuroscience Letters, 2003, 340, 158-160.	1.0	1
95	A Novel Mutation in the PSEN2 Gene (T430M) Associated With Variable Expression in a Family With Early-Onset Alzheimer Disease. Archives of Neurology, 2003, 60, 1149.	4.9	46
96	Frequency of Mutations in the Presenilin and Amyloid Precursor Protein Genes in Early-Onset Alzheimer Disease in Spain. Archives of Neurology, 2002, 59, 1759.	4.9	103
97	A novel mutation (V89L) in the presenilin 1 gene in a family with early onset Alzheimer's disease and marked behavioural disturbances. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 266-269.	0.9	51
98	Further extension of the H1 haplotype associated with progressive supranuclear palsy. Movement Disorders, 2002, 17, 550-556.	2.2	61
99	Detection of the presenilin 1 gene mutation (M139T) in early-onset familial Alzheimer disease in Spain. Neuroscience Letters, 2001, 299, 239-241.	1.0	12
100	Analysis of the coding and the 5â€² flanking regions of the Î±-synuclein gene in patients with Parkinson's disease. Movement Disorders, 2001, 16, 1115-1119.	2.2	23
101	Alzheimer disease is not associated with polymorphisms in the angiotensinogen and renin genes. American Journal of Medical Genetics Part A, 2001, 105, 761-764.	2.4	16
102	Significant association between the tau gene A0/A0 genotype and Parkinson's disease. Annals of Neurology, 2000, 47, 242-245.	2.8	129
103	A Novel Presenilin 1 Mutation (Leu166Arg) Associated With Early-Onset Alzheimer Disease. Archives of Neurology, 2000, 57, 485.	4.9	19
104	Identification of a novel polymorphism in the promoter region of the tau gene highly associated to progressive supranuclear palsy in humans. Neuroscience Letters, 1999, 275, 183-186.	1.0	56
105	Î±-Antichymotrypsin gene polymorphism and risk for Alzheimer's disease in the Spanish population. Neuroscience Letters, 1998, 240, 107-109.	1.0	26
106	Apolipoprotein E Ïµ4 alleles and meiotic origin of non-disjunction in Down syndrome children and in their corresponding fathers and mothers. Neuroscience Letters, 1998, 248, 1-4.	1.0	11
107	Significant Changes in the Tau A0 and A3 Alleles in Progressive Supranuclear Palsy and Improved Genotyping by Silver Detection. Archives of Neurology, 1998, 55, 1122.	4.9	85
108	The genotype 2/2 of the presenilin-1 polymorphism is decreased in Spanish early-onset Alzheimer's disease. Neuroscience Letters, 1997, 227, 201-204.	1.0	26

#	Article	IF	Citations
109	Low apolipoprotein E epsilon4 allele frequency in the population of Catalonia (Spain) determined by PCR-RFLP and Laser fluorescent sequencer. European Journal of Epidemiology, 1997, 13, 841-843.	2.5	9